Biotechnology News

First patients dosed at City of Hope and the University of Alabama at BirminghamDOC-RM recently featured as a Trial-in-Progress presentation at the 2026 ASCO Annual MeetingFDA Fast Track designation...

Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company’s large, randomized Phase II study, OVATION...

20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development

Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded...

NewGen’s total shares outstanding count expected to reach 5.9 million following recently announced share issuance, bolstering market capitalization NewGen’s agreed 13% stake in K25.ai is now valued...

SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it...

PETACH TIKVA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by...

CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

Media Release Pooled analysis of five efti trials (presented at ASCO 2026) reinforced efti's mechanism of action, tying immune activation to a 7.7-month median overall survival benefit in biological...

SAN CARLOS, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor...